{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:59:17Z","timestamp":1775843957927,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/bf03262473","type":"journal-article","created":{"date-parts":[[2012,12,29]],"date-time":"2012-12-29T20:15:15Z","timestamp":1356812115000},"page":"391-401","source":"Crossref","is-referenced-by-count":6,"title":["A Critical Review of the Use of Carvedilol in Ischemic Heart Disease"],"prefix":"10.1007","volume":"12","author":[{"given":"Carol","family":"Chen-Scarabelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"Louis","family":"Saravolatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahya","family":"Murad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Shi","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waqas","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Di Rezze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodeo","family":"Abrencillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tova","family":"Gardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh K.","family":"Gidwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Saravolatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Faggian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziano M.","family":"Scarabelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,29]]},"reference":[{"issue":"5","key":"2473_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1586\/erc.09.15","volume":"7","author":"GC Fonarow","year":"2009","unstructured":"Fonarow GC. Role of carvedilol controlled-release in cardiovascular disease. Expert Rev Cardiovasc Ther 2009; 7(5): 483\u201398","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"Suppl. F","key":"2473_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/eurheartj\/16.suppl_F.38","volume":"16","author":"GZ Feuerstein","year":"1995","unstructured":"Feuerstein GZ, Ruffolo Jr RR. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995; 16 Suppl. F: 38\u201342","journal-title":"Eur Heart J"},{"issue":"4","key":"2473_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0002-8703(99)70217-6","volume":"137","author":"R Senior","year":"1999","unstructured":"Senior R, Basu S, Kinsey C, et al. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 1999; 137 (4 Pt 1): 646\u201352","journal-title":"Am Heart J"},{"issue":"11A","key":"2473_CR4","doi-asserted-by":"publisher","first-page":"41L","DOI":"10.1016\/S0002-9149(97)00847-3","volume":"80","author":"GZ Feuerstein","year":"1997","unstructured":"Feuerstein GZ, Bril A, Ruffolo Jr RR. Protective effects of carvedilol in the myocardium. Am J Cardiol 1997; 80(11A): 41L\u201345L","journal-title":"Am J Cardiol"},{"issue":"1\u20132","key":"2473_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0014-2999(96)00549-3","volume":"314","author":"H Brunvand","year":"1996","unstructured":"Brunvand H, Fr\u0142yland L, Hexeberg E, et al. Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury. Eur J Pharmacol 1996; 314(1\u20132): 99\u2013107","journal-title":"Eur J Pharmacol"},{"issue":"Suppl.B","key":"2473_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/eurheartj\/17.suppl_B.24","volume":"17","author":"GZ Feuerstein","year":"1996","unstructured":"Feuerstein GZ, Ruffolo Jr RR. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 1996; 17 Suppl. B: 24\u20139","journal-title":"Eur Heart J"},{"issue":"5","key":"2473_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000138616","volume":"39","author":"AJ Nichols","year":"1989","unstructured":"Nichols AJ, Sulpizio AC, Ashton DJ, et al. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology 1989; 39(5): 327\u201336","journal-title":"Pharmacology"},{"issue":"5","key":"2473_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","volume":"27","author":"S Yusuf","year":"1985","unstructured":"Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27(5): 335\u201371","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"2473_CR9","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1097\/00005344-199424060-00001","volume":"24","author":"O Hansen","year":"1994","unstructured":"Hansen O, Johansson BW, Nilsson-Ehle P, et al. Effects of carvedilol on the metabolic, hemodynamic, and electrocardiographic responses to increased plasma epinephrine in normal subjects. J Cardiovasc Pharmacol 1994; 24(6): 853\u20139","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"2473_CR10","first-page":"S41","volume":"11","author":"GZ Feuerstein","year":"1993","unstructured":"Feuerstein GZ, Yue TL, Cheng HY, et al. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens Suppl 1993; 11(4): S41\u20138","journal-title":"J Hypertens Suppl"},{"issue":"3","key":"2473_CR11","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/S0022-3565(25)09673-9","volume":"273","author":"TL Yue","year":"1995","unstructured":"Yue TL, Wang X, Gu JL, et al. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther 1995; 273(3): 1442\u20139","journal-title":"J Pharmacol Exp Ther"},{"issue":"2\u20133","key":"2473_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0014-2999(98)00494-4","volume":"356","author":"H Brunvand","year":"1998","unstructured":"Brunvand H, Liu G, Ma XL, et al. SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits. Eur J Pharmacol 1998; 356(2\u20133): 193\u20138","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"2473_CR13","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1006\/jmcc.1994.1115","volume":"26","author":"OH Bing","year":"1994","unstructured":"Bing OH. Hypothesis: apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload. J Mol Cell Cardiol 1994; 26(8): 943\u20138","journal-title":"J Mol Cell Cardiol"},{"issue":"12","key":"2473_CR14","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1172\/JCI118747","volume":"97","author":"E Teiger","year":"1996","unstructured":"Teiger E, Than VD, Richard L, et al. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest 1996; 97(12): 2891\u20137","journal-title":"J Clin Invest"},{"issue":"5","key":"2473_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/cvr\/26.5.518","volume":"26","author":"A Bril","year":"1992","unstructured":"Bril A, Slivjak M, DiMartino MJ, et al. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol. Cardiovasc Res 1992; 26(5): 518\u201325","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2473_CR16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0022-3565(25)12798-5","volume":"277","author":"XL Ma","year":"1996","unstructured":"Ma XL, Yue TL, Lopez BL, et al. Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther 1996; 277(1): 128\u201336","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl. 2","key":"2473_CR17","first-page":"138","volume":"27","author":"K Dr\u00e1bikov\u00e1","year":"2006","unstructured":"Dr\u00e1bikov\u00e1 K. On the antioxidant activity of carvedilol in human polymorphonuclear leukocytes in vitro and ex vivo. Neuroendocrinol Lett 2006; 27 Suppl. 2: 138\u201340","journal-title":"Neuroendocrinol Lett"},{"issue":"7","key":"2473_CR18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.amjmed.2003.10.029","volume":"116","author":"K Yasunari","year":"2004","unstructured":"Yasunari K, Maeda K, Nakamura M, et al. Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med 2004; 116(7): 460\u20135","journal-title":"Am J Med"},{"issue":"7","key":"2473_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/10715760600690329","volume":"40","author":"P Szajerski","year":"2006","unstructured":"Szajerski P, Zielonka J, Sikora A, et al. Radical scavenging and NO-releasing properties of selected beta-adrenoreceptor antagonists. Free Radic Res 2006 Jul; 40(7): 741\u20132","journal-title":"Free Radic Res"},{"issue":"13","key":"2473_CR20","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1016\/j.bmc.2006.02.023","volume":"14","author":"A Gomes","year":"2006","unstructured":"Gomes A, Costa D, Lima JL, et al. Antioxidant activity of beta-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species? Bioorg Med Chem 2006 Jul 1; 14(13): 4568\u201377","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"2473_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0006-2952(01)00651-7","volume":"62","author":"K Oettl","year":"2001","unstructured":"Oettl K, Greilberger J, Zangger K, et al. Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity. Biochem Pharmacol 2001 Jul 15; 62(2): 241\u20138","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"2473_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000139331","volume":"51","author":"BL Lopez","year":"1995","unstructured":"Lopez BL, Christopher TA, Yue TL, et al. Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radicalinduced endothelial dysfunction. Pharmacology 1995 Sep; 51(3): 165\u201373","journal-title":"Pharmacology"},{"issue":"4","key":"2473_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0165-6147(90)90068-J","volume":"11","author":"SW Werns","year":"1990","unstructured":"Werns SW, Lucchesi BR. Free radicals and ischemic tissue injury. Trends Pharmacol Sci 1990; 11(4): 161\u20136","journal-title":"Trends Pharmacol Sci"},{"issue":"2\u20133","key":"2473_CR24","first-page":"277","volume":"214","author":"TL Yue","year":"1992","unstructured":"Yue TL, McKenna PJ, Ruffolo Jr RR, et al. Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol 1992; 214(2\u20133): 277\u201380","journal-title":"Eur J Pharmacol"},{"issue":"5789","key":"2473_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/288373a0","volume":"288","author":"RF Furchgott","year":"1980","unstructured":"Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980 Nov 27; 288(5789): 373\u20136","journal-title":"Nature"},{"issue":"2","key":"2473_CR26","first-page":"H611","volume":"262","author":"P Kubes","year":"1992","unstructured":"Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Am J Physiol 1992; 262 (2 Pt 2): H611\u20135","journal-title":"Am J Physiol"},{"issue":"6","key":"2473_CR27","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1161\/01.ATV.13.6.771","volume":"13","author":"AM Lefer","year":"1993","unstructured":"Lefer AM, Ma XL. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arterioscler Thromb 1993; 13(6): 771\u20136","journal-title":"Arterioscler Thromb"},{"issue":"7","key":"2473_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.amjhyper.2007.01.019","volume":"20","author":"AJ Bank","year":"2007","unstructured":"Bank AJ, Kelly AS, Thelen AM, et al. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens 2007; 20(7): 777\u201383","journal-title":"Am J Hypertens"},{"issue":"2","key":"2473_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/hrt.2006.087999","volume":"93","author":"K Nishioka","year":"2007","unstructured":"Nishioka K, Nakagawa K, Umemura T, et al. Carvedilol improves endothelium-dependent vasodilation in patients with dilated cardiomyopathy. Heart 2007; 93(2): 247\u20138","journal-title":"Heart"},{"issue":"3","key":"2473_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000138836","volume":"43","author":"SA Hamburger","year":"1991","unstructured":"Hamburger SA, Barone FC, Feuerstein GZ, et al. Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology 1991; 43(3): 113\u201320","journal-title":"Pharmacology"},{"issue":"5","key":"2473_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2165\/00003495-200868050-00002","volume":"68","author":"M Galderisi","year":"2008","unstructured":"Galderisi M, D\u2019Errico A. Beta-blockers and coronary flow reserve: the importance of a vasodilatory action. Drugs 2008; 68(5): 579\u201390","journal-title":"Drugs"},{"issue":"3","key":"2473_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00005344-199609000-00010","volume":"28","author":"H Brunvand","year":"1996","unstructured":"Brunvand H, Kvitting PM, Rynning SE, et al. Carvedilol protects against lethal reperfusion injury through antiadrenergic mechanisms. J Cardiovasc Pharmacol 1996; 28(3): 409\u201317","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"2473_CR33","first-page":"S55","volume":"11","author":"O Hansen","year":"1993","unstructured":"Hansen O, Johansson BW. Benefits of non-selective versus cardioselective beta-blockers in acute myocardial infarction in hypertensive patients. J Hypertens Suppl 1993; 11(4): S55\u201360","journal-title":"J Hypertens Suppl"},{"issue":"1","key":"2473_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1161\/01.CIR.96.1.183","volume":"96","author":"S Basu","year":"1997","unstructured":"Basu S, Senior R, Raval U, et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction: a placebo-controlled, randomized trial. Circulation 1997; 96(1): 183\u201391","journal-title":"Circulation"},{"issue":"3","key":"2473_CR35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S1388-9842(00)00098-2","volume":"2","author":"HJ Dargie","year":"2000","unstructured":"Dargie HJ. Design and methodology of the CAPRICORN trial: a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 2000 Sep; 2(3): 325\u201332","journal-title":"Eur J Heart Fail"},{"issue":"9266","key":"2473_CR36","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","volume":"357","author":"HJ Dargie","year":"2001","unstructured":"Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001 May 5; 357(9266): 1385\u201390","journal-title":"Lancet"},{"issue":"9A","key":"2473_CR37","doi-asserted-by":"publisher","first-page":"13B","DOI":"10.1016\/j.amjcard.2004.01.018","volume":"93","author":"WS Colucci","year":"2004","unstructured":"Colucci WS. Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN). Am J Cardiol 2004; 93(9A): 13B\u20136B","journal-title":"Am J Cardiol"},{"issue":"4","key":"2473_CR38","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ahj.2007.06.002","volume":"154","author":"GC Fonarow","year":"2007","unstructured":"Fonarow GC, Lukas MA, Robertson M, et al. Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). Am Heart J 2007; 154(4): 637\u201344","journal-title":"Am Heart J"},{"issue":"Suppl.F","key":"2473_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/eurheartj\/17.suppl_F.43","volume":"17","author":"S Basu","year":"1996","unstructured":"Basu S, Senior R, Raftery EB, et al. The association between cardiac events and myocardial ischaemia following thrombolysis in acute myocardial infarction and the impact of carvedilol. Eur Heart J 1996; 17 Suppl. F: 43\u20137","journal-title":"Eur Heart J"},{"issue":"13","key":"2473_CR40","doi-asserted-by":"publisher","first-page":"6189","DOI":"10.1073\/pnas.90.13.6189","volume":"90","author":"EH Ohlstein","year":"1993","unstructured":"Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993; 90(13): 6189\u201393","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2473_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/00005344-199302000-00006","volume":"21","author":"CP Sung","year":"1993","unstructured":"Sung CP, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993; 21(2): 221\u20137","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"2473_CR42","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0022-3565(24)37059-4","volume":"283","author":"CP Sung","year":"1997","unstructured":"Sung CP, Arleth AJ, Eichman C, et al. Carvedilol, a multiple-action neurohumoral antagonist, inhibits mitogen-activated protein kinase and cell cycle progression in vascular smooth muscle cells. J Pharmacol Exp Ther 1997; 283(2): 910\u20137","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2473_CR43","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1016\/j.ahj.2003.08.003","volume":"147","author":"KS Cha","year":"2004","unstructured":"Cha KS, Kim MH, Kim JW, et al. Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting. Am Heart J 2004 Feb; 147(2): E7","journal-title":"Am Heart J"},{"issue":"1","key":"2473_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3904\/kjim.2011.26.1.41","volume":"26","author":"HK Kim","year":"2011","unstructured":"Kim HK, Hong YJ, Jeong MH, et al. Two-year clinical outcome after carvedilol-loaded stent implantation in patients with coronary artery disease. Korean J Intern Med 2011 Mar; 26(1): 41\u20136","journal-title":"Korean J Intern Med"},{"issue":"13","key":"2473_CR45","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1161\/01.CIR.101.13.1512","volume":"101","author":"PW Serruys","year":"2000","unstructured":"Serruys PW, Foley DP, H\u00f6fling B, et al. Carvedilol for prevention of restenosis after directional coronary atherectomy: final results of the European carvedilol atherectomy restenosis (EUROCARE) trial. Circulation 2000 Apr 4; 101(13): 1512\u20138","journal-title":"Circulation"},{"issue":"2","key":"2473_CR46","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1161\/01.CIR.0000108928.25690.94","volume":"109","author":"RN Doughty","year":"2004","unstructured":"Doughty RN, Whalley GA, Walsh HA, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004; 109(2): 201\u20136","journal-title":"Circulation"},{"issue":"25","key":"2473_CR47","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1161\/01.CIR.101.25.2981","volume":"101","author":"MG Sutton","year":"2000","unstructured":"Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101(25): 2981\u20138","journal-title":"Circulation"},{"issue":"2","key":"2473_CR48","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/01.CIR.98.2.149","volume":"98","author":"K Ono","year":"1998","unstructured":"Ono K, Matsumori A, Shioi T, et al. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998; 98(2): 149\u201356","journal-title":"Circulation"},{"issue":"2","key":"2473_CR49","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijcard.2005.08.065","volume":"111","author":"B Li","year":"2006","unstructured":"Li B, Liao YH, Cheng X, et al. Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. Int J Cardiol 2006 Aug 10; 111(2): 247\u201355","journal-title":"Int J Cardiol"},{"issue":"8","key":"2473_CR50","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1161\/01.RES.0000163017.13772.3a","volume":"96","author":"O Dewald","year":"2005","unstructured":"Dewald O, Zymek P, Winkelmann K, et al. CCL2\/Monocyte Chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005; 96(8): 881\u20139","journal-title":"Circ Res"},{"issue":"4","key":"2473_CR51","doi-asserted-by":"publisher","first-page":"H1847","DOI":"10.1152\/ajpheart.00434.2006","volume":"292","author":"MR Bergman","year":"2007","unstructured":"Bergman MR, Teerlink JR, Mahimkar R, et al. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 2007; 292(4): H1847\u201360","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"8","key":"2473_CR52","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/S0735-1097(03)01057-X","volume":"42","author":"EF Lewis","year":"2003","unstructured":"Lewis EF, Moye LA, Rouleau JL, et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol 2003; 42(8): 1446\u201353","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2473_CR53","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ijcard.2010.08.018","volume":"153","author":"G Cimmino","year":"2011","unstructured":"Cimmino G, Ibanez B, Giannarelli C, et al. Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol. Int J Cardiol 2011 Dec; 153(3): 256\u201361","journal-title":"Int J Cardiol"},{"issue":"5","key":"2473_CR54","first-page":"476","volume":"23","author":"YD Tang","year":"2001","unstructured":"Tang YD. Comparative effects of carvedilol and metoprolol in preventing from left ventricular remodeling after acute myocardial infarction in rats [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2001; 23(5): 476\u201380","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"issue":"1","key":"2473_CR55","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/oxfordjournals.eurheartj.a059826","volume":"12","author":"R Does van der","year":"1991","unstructured":"van der Does R. Treatment of chronic stable angina with carvedilol in comparison with nifedipine s.r. Eur Heart J 1991; 12(1): 60\u20134","journal-title":"Eur Heart J"},{"issue":"Suppl. 1","key":"2473_CR56","first-page":"S93","volume":"70","author":"T Wendt","year":"1992","unstructured":"Wendt T. Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease. Clin Investig 1992; 70 Suppl. 1: S93\u20137","journal-title":"Clin Investig"},{"issue":"Suppl. 11","key":"2473_CR57","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1097\/00005344-198710111-00027","volume":"10","author":"T Wendt","year":"1987","unstructured":"Wendt T, van der Does R, Schraeder R, et al. Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S147\u201350","journal-title":"J Cardiovasc Pharmacol"},{"issue":"8","key":"2473_CR58","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/0002-9149(87)91089-7","volume":"59","author":"A Lahiri","year":"1987","unstructured":"Lahiri A. Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris. Am J Cardiol 1987; 59(8): 769\u201374","journal-title":"Am J Cardiol"},{"issue":"Suppl. 11","key":"2473_CR59","first-page":"S137","volume":"10","author":"JC Kaski","year":"1987","unstructured":"Kaski JC, Rodriguez-Plaza L, Brown J, et al. Efficacy of carvedilol in exercise-induced myocardial ischemia. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S137\u201340","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl. 11","key":"2473_CR60","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1097\/00005344-198710111-00026","volume":"10","author":"SM Jamal","year":"1987","unstructured":"Jamal SM, Freedman SB, Thomson A, et al. Antianginal efficacy of carvedilol, a new beta-blocker with vasodilating action. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S141\u20136","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"2473_CR61","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S0002-9149(86)80010-8","volume":"58","author":"EA Rodrigues","year":"1986","unstructured":"Rodrigues EA, Lahiri A, Hughes LO, et al. Antianginal efficacy of carvedilol, a beta-blocking drug with vasodilating activity. Am J Cardiol 1986; 58(10): 916\u201321","journal-title":"Am J Cardiol"},{"issue":"4","key":"2473_CR62","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1536\/ihj.31.449","volume":"31","author":"H Kishida","year":"1990","unstructured":"Kishida H, Saito T, Fukuma N, et al. Evaluation of a new vasodilating beta-blocking agent, carvedilol, in exertional angina using holter monitoring. Jpn Heart J 1990; 31(4): 449\u201360","journal-title":"Jpn Heart J"},{"issue":"Suppl. 3","key":"2473_CR63","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000175931","volume":"82","author":"L Storstein","year":"1993","unstructured":"Storstein L. Carvedilol: clinical experience in arrhythmias. Cardiology 1993; 82 Suppl. 3: 29\u201333","journal-title":"Cardiology"},{"issue":"1","key":"2473_CR64","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S0003-4975(99)01267-9","volume":"69","author":"CW Hogue Jr","year":"2000","unstructured":"Hogue Jr CW, Hyder ML. Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment. Ann Thorac Surg 2000; 69(1): 300\u20136","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"2473_CR65","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1253\/circj.72.588","volume":"72","author":"J Tsuboi","year":"2008","unstructured":"Tsuboi J, Kawazoe K, Izumoto H, et al. Postoperative treatment with carvedilol, a beta-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting. Circ J 2008; 72(4): 588\u201391","journal-title":"Circ J"},{"issue":"6","key":"2473_CR66","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0002-9149(03)00842-7","volume":"92","author":"JC Merritt","year":"2003","unstructured":"Merritt JC, Niebauer M, Tarakji K, et al. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol 2003 Sep 15; 92(6): 735\u20136","journal-title":"Am J Cardiol"},{"issue":"1","key":"2473_CR67","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijcard.2007.03.123","volume":"126","author":"S Acikel","year":"2008","unstructured":"Acikel S, Bozbas H, Gultekin B, et al. Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. Int J Cardiol 2008 May 7; 126(1): 108\u201313","journal-title":"Int J Cardiol"},{"issue":"9","key":"2473_CR68","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.hrthm.2007.04.022","volume":"4","author":"M Haghjoo","year":"2007","unstructured":"Haghjoo M, Saravi M, Hashemi MJ, et al. Optimal beta-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol. Heart Rhythm 2007 Sep; 4(9): 1170\u20134","journal-title":"Heart Rhythm"},{"issue":"4","key":"2473_CR69","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jacc.2004.09.076","volume":"45","author":"J McMurray","year":"2005","unstructured":"McMurray J, K\u00f8ber L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45(4): 525\u201330","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"2473_CR70","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1053\/euhj.1999.1984","volume":"21","author":"G Cice","year":"2000","unstructured":"Cice G, Tagliamonte E, Ferrara L, et al. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study. Eur Heart J 2000; 21(15): 1259\u201364","journal-title":"Eur Heart J"},{"issue":"Suppl. 1","key":"2473_CR71","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1097\/00005344-199219001-00023","volume":"19","author":"R Senior","year":"1992","unstructured":"Senior R, M\u00fcller-Beckmann B, DasGupta P, et al. Effects of carvedilol on ventricular arrhythmias. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S117\u201321","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03262473.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03262473\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03262473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03262473.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:25:23Z","timestamp":1745940323000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03262473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["2473"],"URL":"https:\/\/doi.org\/10.1007\/bf03262473","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}